Terug naar bedrijfspagina

Nieuws over BioSenic (Bone Therapeutics)

12/04/2024 BioSenic - provides further information on its restructuring plan (12.04.2024)

11/04/2024 BioSenic - and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles (11.04.2024)

12/03/2024 BioSenic - releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease (12.03.2024)

02/02/2024 BioSenic - raises €500,000 in private placement of new shares with established new investors (02.02.2024)

30/01/2024 Biosenic - BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform (30.01.2024)

25/01/2024 BioSenic - présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024 (25.01.2024)

23/01/2024 BioSenic - files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis (23.01.2024)

15/01/2024 BioSenic - reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment (15.01.2024)

09/01/2024 BioSenic - signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds (09.01.2024)

08/12/2023 BioSenic - ERRATUM - on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease (08.12.2023)

06/12/2023 BioSenic - on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease. (06.12.2023)

04/05/2023 BioSenic - identifies key biomarkers for cGvHD and submits patent to EPO (04.05.2023)

16/03/2023 BioSenic - delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population (16.03.2023)

23/02/2023 BioSenic - optimizes statistical analysis for its ongoing ALLOB Phase IIb study for high-risk tibial fractures, requiring fewer patients and completes patient recruitment (23.02.2023)

14/02/2023 BioSenic - announces initiation of coverage by Portzamparc and Gilbert Dupont (14.02.2023)

08/02/2023 BioSenic - announces the approval and publication of the Prospectus for listing and admission to trading of the shares and subscription rights issued in the context of the capital increase by way of in kind contributions of Medsenic 51% participation (08.02.2023)

27/01/2023 BioSenic - nomme Yves Sagot en qualité d’Administrateur indépendant (27.01.2023)

01/12/2022 BioSenic (Bone Therapeutics) - Information on the total number of voting rights and shares (01.12.2022)

25/10/2022 Bone Therapeutics - to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 million (25.10.2022)

21/10/2022 Bone Therapeutics - provides Third Quarter 2022 Business Update (21.10.2022)

07/10/2022 Bone Therapeutics - to regain worldwide rights to ALLOB (07.10.2022)

07/09/2022 Bone Therapeutics - reports half year 2022 results (07.09.2022)

01/07/2021 Bone Therapeutics - publishes results of ALLOB Phase I/IIa study for the treatment of delayed-union fractures in Stem Cell Research & Therapy (persbericht 01.07.2021)

15/06/2021 Bone Therapeutics - Provides First Quarter 2021 Business Update (15.06.2021)

20/08/2020 Bone Therapeutics - announces expansion of its pipeline supported by funding from the Walloon Region (20.8.2020)

13/08/2020 Bone Therapeutics - receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study (13.8.2020)

18/05/2020 Bone Therapeutics - treats first patients in pivotal JTA-004 phaseIII knee oesteoarthritis study (18.5.2020)

20/04/2020 2020 04 - Bedrijfsbezoek bij Bone Therapeutics

26/03/2020 Bone Therapeutics - appoints Stefanos Theoharis as Chief Business Officer (26.3.2020)

23/03/2020 Bone Therapeutics - receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates (23.3.2020)

11/03/2020 Bone Therapeutics - announces 2019 full year results (11.3.2020)

11/02/2020 Bone Therapeutics - to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the Orthopaedic Research Society (11.2.2020)

04/07/2019 Bone Therapeutics - Transparency notification received from Mr. J. Reymann (4.7.2019)

28/06/2019 BONE THERAPEUTICS SUCCESSFULLY RAISES EUR 8.5 MILLION (28.6.2019)

27/06/2019 BONE THERAPEUTICS - raise capital trough private placement of new shares (27.6.2019)

21/06/2019 Bone Therapeutics - Information on the total number of voting rights and shares (21.6.2019)

13/06/2019 Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study lumbar spinal fusion procedure (13.6.2019)

29/05/2019 Bone Therapeutics - Information on the total number of voting rights and shares (29.5.2019)

24/05/2019 Bone Therapeutics - notulen buitengewone algemene vergadering (24.5.2019)

24/05/2019 Bone Therapeutics to present data at TERMIS European Chapter Meeting 2019 (24.5.2019)

07/05/2019 Bone Therapeutics - First Quarter 2019 Business Update (7.5.2019)

12/03/2019 Bone Therapeutics appoints Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer (12/03/19)

29/01/2019 Bone Therapeutics; Evenement"Wallonië wil de celtherapie veroveren" is een groot succes (29.1.2019)

22/01/2019 Bone Therapeutics announces 2019 business outlook and reports yearen d cash position (22.1.2019)

04/01/2019 BoneTherapeutics announces attendance at the 37th Annual J.P. Morgan Healthcare Conference (4.1.2019)

11/12/2018 Bone Therapeutics SA- Transparency notification received from S.R.I.W. SA and Sofipôle SA (11.12.2018)

29/11/2018 Bone Therapeutics-information on the total number of voting rights and shares (29.11.2018)

08/11/2018 2018 09 - Interview met ceo Thomas Lienard

07/11/2018 Bone Therapeutics Business Update for Third Quarter 2018 (7.11.2018)

06/11/2018 Bone Therapeutics announces conclusions from interim analysis of Phase III PREOB study in hip osteonecrosis

29/10/2018 Bone Therapeutics announces appointment of Linda Lebon as Chief Regulatory Officer (29.10.2018)

18/10/2018 Bone tackelt knie-artrose (KBC)

17/10/2018 Bone Therapeutics- injectie viscosupplement JTA-004 leidt tot een sterkere pijnvermindering bij knieartrose dan de referentie in een eerste studie (17.10.2018)

27/09/2018 Bone Therapeutics- Information on the total number of voting rights and shares (27.9.2018)

14/09/2018 Bone Therapeutics neemt volgende ALLOB stap (KBC)

14/09/2018 Bone Therapeutics SA announces final results from Phase I/IIA ALLOB delayed-union fracture study (14.9.2018)

30/08/2018 Bone Therapeutics SA announces H1 results for 2018 (30.8.2018)

08/08/2018 Bone Therapeutics Notice of Half Year 2018 Results (8.8.2018)

09/11/2017 Aegon, Bone Therapeutics en bpost (KBC Groep)

16/02/2015 2015 02 - Interview met Enrico Bastianelli en Wim Goemaere